Olivier Colomban

CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Benoît You, Patrick Robelin, Michel Tod et al. · Clinical Cancer Research · 2020 · 132 citations

Medicine, Oncology, Pharmacology +13

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study

Benoît You, Christopher Purdy, Larry J. Copeland et al. · Journal of Clinical Oncology · 2022 · 75 citations · Full text

Medicine, Oncology, Pharmacology +17

The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: Data from CALYPSO trial (a GINECO-GCIG study)

Benoît You, Olivier Colomban, M. Heywood et al. · Gynecologic Oncology · 2013 · 74 citations

Medicine, Gynecology, Oncology +15

Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study

Olivier Colomban, Michel Tod, Alexandra Léary et al. · Clinical Cancer Research · 2019 · 68 citations · Full text

Medicine, Gynecology, Oncology +17

Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7)

Olivier Colomban, Michel Tod, Julien Péron et al. · JNCI Cancer Spectrum · 2020 · 44 citations · Full text

Medicine, Oncology, Pharmacology +15